Editas Medicine

Company Overview

Editas Medicine is a leading gene editing company dedicated to developing medicines to treat people living with serious diseases around the world. The company has developed a proprietary genome editing platform based on CRISPR technology that uses CRISPR gene editing, a revolutionary approach to developing medicines. The company claims to be the only human genome editing company with a platform comprising of CRISPR/Cas9, CRISPR/Cas12a, and engineered forms of both of these CRISPR systems. Further, the company can create gene-editing molecules for more than 95% of the human genome.

Editas Medicine is working on making in vivo CRISPR medicines (editing occurs inside the body), as well as ex vivo engineered cell medicines (editing occurs outside the body) and edited cells that are administered to patients (engineered cell medicines). The company’s mission is to translate the power and potential of genome editing into a broad class of CRISPR-based medicines that transform the lives of people living with serious diseases.

Financial Highlights (FY 2023)

Company's Business Segments

• Research and Pipeline : In Vivo Medicines, Ex Vivo Cell Medicines
• CRISPR Gene Editing : Genetics, Genomic Medicine, CRISPR Gene Editing
• For Patients : Transformative Medicines